The study found no mean difference in all-cause healthcare costs for patients with newly diagnosed nonvalvular atrial fibrillation initiating treatment with dabigatran versus warfarin.
John C. White, DPM, MS
Advertisement
Articles by John C. White, DPM, MS
Advertisement
Latest Updated Articles
- Predictors of Healthcare Costs After Initiating Dabigatran Versus Warfarin
Published: February 2nd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Axatilimab: A New Frontier for Steroid-Refractory Chronic GVHD
2
CHEST 2025: Exploring the Link Between GLP-1 Receptor Agonists, Type 2 Diabetes, and Asthma Risk
3
Immunization and Vigilance: Preventing Infections in T-Cell Modifying Therapies
4
World Standards Week 2025: Advancing Quality and Patient Safety Standards to Shape Pharmacy Practice and Innovation
5
